IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.tps11582
Abstract: • Unlike CAR-T cells that recognize cell surface proteins, T-cell receptors can recognize antigenic epitopes of intracellular proteins that are processed and presented on the surface of the cancer cell in the context of human… read more here.
Keywords: ignyte eso; cell; master protocol; hla ... See more keywords
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.2500
Abstract: 2500 Background: Letetresgene autoleucel (lete-cel) is an autologous engineered T cell receptor therapy targeting the NY-ESO-1 cancer testis antigen highly expressed in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS). Lete-cel pilots showed promising efficacy… read more here.
Keywords: ignyte eso; cel; analysis; cell ... See more keywords